Authorized Generics Benefit Consumers: Report

Law360, New York (April 18, 2007, 12:00 AM EDT) -- While authorized generic drugs in the market have become more prevalent in the last five years, paragraph IV certifications have not declined as a result, according to a report released Wednesday.

Analysis Group on Tuesday released a report that found that a surge in authorized generic entry has not contributed to delays in the timing of entry and has instead benefited consumers through lower drug prices.

“The rate of paragraph IV certifications is higher than it has ever been,” the report stated. “Sufficient incentives remain so...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.